Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSPD1 | P10809 | 2/20 | 1.00 |
| ▸ | HSPE1 | P61604 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.86 |
| ▸ | USP2 | O75604 | 1/20 | 0.86 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.84 |
| ▸ | DRD1 | P21728 | 1/20 | 0.84 |
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
| ▸ | RAB9A | P51151 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248559 | 1.00 | HSPD1 (1.00) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| SCHEMBL29523079 | 1.00 | HSPD1 (1.00) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| SCHEMBL29355814 | 1.00 | HSPD1 (1.00) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| SCHEMBL19708763 | 1.00 | HSPD1 (1.00) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| Eprinomectin SCHEMBL29392105 | 0.99 | HSPD1 (0.98) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| Eprinomectin SCHEMBL120548 | 0.99 | HSPD1 (0.98) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| Propylene Glycol SCHEMBL9901967 | 0.97 | HSPD1 (0.94) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| SCHEMBL13309158 | 0.96 | HSPD1 (0.93) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| SCHEMBL19708888 | 0.96 | HSPD1 (0.91) | HSPD1HSPE1MEN1KMT2AUSP2 | |
| SCHEMBL3913613 | 0.96 | HSPD1 (0.91) | HSPD1HSPE1MEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12098009-B2 | Stand alone dispensing pouch | Boehringer Ingelheim Animal Health USA Inc. (US) | 2024-09-24 | — | — | US | disclosed |
| US-11985976-B2 | Mixture of mectins and pyrethroids and uses thereof | VALENT BIOSCIENCES LLC (US) | 2024-05-21 | — | — | US | disclosed |
| CN-115768263-A | Mixtures of pyrethroids and rhzomorphs and use thereof | 瓦伦特生物科学有限责任公司 | 2023-03-07 | — | — | CN | disclosed |
| US-11583545-B2 | Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof | Boehringer Ingelheim Animal Health USA Inc. (US) | 2023-02-21 | — | — | US | disclosed |
| EP-3599855-B1 | DELAYED RELEASE FEED-THROUGH VETERINARY COMPOSITIONS WITH OVICIDAL AND LARVICIDAL ACTIVITY AGAINST SUSCEPTIBLE AND RESISTANT STRAINS OF PARASITES IN RUMINANTS' FECES, USE OF THESE COMPOSITIONS, METHOD FOR DELAYING THE RELEASE OF THESE COMPOSITIONS | Champion USA LLC (US) | 2022-03-02 | — | — | EP | disclosed |
| WO-2021252584-A1 | A MIXTURE OF PYRETHROIDS AND MECTINS AND USES THEREOF | VALENT BIOSCIENCES LLC (US) | 2021-12-16 | — | — | WO | disclosed |
| US-20210386065-A1 | MIXTURE OF MECTINS AND PYRETHROIDS AND USES THEREOF | VALENT BIOSCIENCES LLC | 2021-12-16 | — | — | US | disclosed |
| EP-3220888-B1 | EPRINOMECTIN PARENTERAL COMPOSITIONS | CEVA SANTE ANIMALE (FR) | 2021-10-27 | — | — | EP | disclosed |
| US-20210315678-A1 | STAND ALONE DISPENSING POUCH | Boehringer Ingelheim Animal Health USA Inc. (US) | 2021-10-14 | — | — | US | disclosed |
| EP-3820401-A1 | STAND ALONE DISPENSING POUCH | Boehringer Ingelheim Animal Health USA Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-1834670-A2 | Anthelmintic compositions containing combinations of avermectins or milbemycins with bis-aryl compounds | Pfizer, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| US-20070042013-A1 | Long acting injectable formulations | MERIAL, INC. | 2007-02-22 | — | — | US | disclosed |
| US-20060128641-A1 | Levamisole, avermectins or similar in pyrrolidone solvent | MERIAL LIMITED | 2006-06-15 | — | — | US | disclosed |
| US-20060105969-A1 | Anthelmintic compositions | BRUCE CHRISTOPHER I | 2006-05-18 | — | — | US | disclosed |
| EP-1551390-A1 | LEVAMISOLE, AVERMECTINS OR SIMILAR IN PYRROLIDONE SOLVENT | Ashmont Holdings Limited (NZ) | 2005-07-13 | — | — | EP | disclosed |
| US-20050118222-A1 | Product to combat ticks and the process for the product's preparation | WOLFF BRUCE ZBIG A (BR) | 2005-06-02 | — | — | US | disclosed |
| WO-2004047795-A2 | CUTANEOUS APPLICATION OF FLUPIRTINE | BAYER HEALTHCARE AG (DE) | 2004-06-10 | — | — | WO | disclosed |
| WO-2004009080-A1 | Levamisole, Avermectins or similar in pyrrolidone solvent | ASHMONT HOLDINGS LIMITED (NZ) | 2004-01-29 | — | — | WO | disclosed |
| US-20030203859-A1 | A combination of a bis-aryl compound (such as fipronil) and an avermectin or milbemycin or derivative useful as parasitic agent | PFIZER INC. | 2003-10-30 | — | — | US | disclosed |
| EP-1066854-A2 | Anthelmintic compositions containing combinations of avermectins or milbemycins with bis-aryl compounds | PFIZER INC. (US) | 2001-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210386065-A1 | MIXTURE OF MECTINS AND PYRETHROIDS AND USES THEREOF | ACHE, DDT, PTMS | HSPD1 1466/4885HSPE1 1503/4885MEN1 58/4885 |
| US-20070042013-A1 | Long acting injectable formulations | LPXN, VIP, VEGFA | HSPD1 4240/4885HSPE1 4142/4885MEN1 2171/4885 |
| US-11583545-B2 | Parasiticidal compositions comprising eprinomectin and praziquantel, methods and uses thereof | EPHX1, GPX4, EPX | HSPD1 1486/4885HSPE1 1182/4885MEN1 3217/4885 |
| US-20060105969-A1 | Anthelmintic compositions | TUBB, TUBA3C, CYP51A1 | HSPD1 376/4885HSPE1 314/4885MEN1 3412/4885 |
| US-11985976-B2 | Mixture of mectins and pyrethroids and uses thereof | ACHE, DDT, PTMS | HSPD1 1466/4885HSPE1 1503/4885MEN1 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.